Ken Griffin Myriad Genetics Inc Put Options Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2025 Aug 14, 2025	SELL	$3.84 - $8.84 $15,360 - $35,360	-4,000 Reduced 21.98%	14,200 $75,000
Q1 2025 May 15, 2025	SELL	$8.87 - $14.98 $22,174 - $37,450	-2,500 Reduced 12.08%	18,200 $161,000
Q4 2024 Feb 14, 2025	BUY	$13.17 - $27.03 $34,242 - $70,278	2,600 Added 14.36%	20,700 $283,000
Q3 2024 Nov 14, 2024	BUY	$23.97 - $28.6 $79,101 - $94,380	3,300 Added 22.3%	18,100 $495,000
Q2 2024 Aug 14, 2024	BUY	$17.98 - $25.47 $8,990 - $12,735	500 Added 3.5%	14,800 $362,000
Q1 2024 May 15, 2024	SELL	$17.59 - $23.59 $165,346 - $221,746	-9,400 Reduced 39.66%	14,300 $304,000
Q4 2023 Feb 14, 2024	BUY	$13.91 - $21.32 $148,837 - $228,124	10,700 Added 82.31%	23,700 $453,000
Q3 2023 Nov 14, 2023	BUY	$15.99 - $23.22 $63,960 - $92,880	4,000 Added 44.44%	13,000 $208,000
Q2 2023 Aug 14, 2023	BUY	$17.56 - $23.76 $105,359 - $142,560	6,000 Added 200.0%	9,000 $208,000
Q1 2023 May 15, 2023	BUY	$15.26 - $23.75 $3,052 - $4,750	200 Added 7.14%	3,000 $69,000
Q4 2022 Feb 14, 2023	BUY	$14.51 - $20.99 $40,628 - $58,771	2,800 New	2,800 $40,000

232

94.1M

450K

14.2K

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $486M
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.